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ABSTRACT Abstract—the modular structure and versatility of antibodies enables one to modify natural immunoglobulins in different ways for various clinical 
applications. rational design and molecular engineering make it possible to directionally modify the molecular size, affinity, specificity, and immunogenicity and 
effector functions of an antibody, as well as to combine them with other functional agents. this review focuses on up-to-date methods of antibody engineering 
for diagnosing and treating various diseases, particularly on new technologies meant to refine the effector functions of therapeutic antibodies.
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Abbreviations: ADcc (antibody-dependent cellular cytotoxicity); cDc (complement-dependent cytotoxicity); MAb (monoclonal antibodies); cH and cL 
(constant domains of antibody heavy and light chains); СНО cells (chinese hamster ovary cells); eGFr (Her1) (epidermal growth factor receptor, cancer 
marker); Fab (antigen-binding fragment of antibody); Fc (constant (crystallizable) antibody fragment); Fcγr (cell receptor of antibody Fc-fragments); Fcrn 
(neonatal receptor of antibody Fc-fragments); Her1 and Her2/neu (cancer markers of tyrosine kinase receptor group); IgA, IgG, IgD, Ige, IgM (A, G, D, e, M 
immunoglobulins (antibodies of the A, G, D, e, M classes)); scFv (single chain fragment variable); PSMA (prostate-specific membrane antigen); VeGF (vascular 
endothelial growth factor); VH and VL (variable domains of heavy and light antibody chains).
INTRODuCTION 
A century ago, antibodies were regarded a “magic bullet” 
that would selectively strike disease hotbeds in the human 
organism (see Paul ehrlich’s nobel Lecture of 1908 [1]). 
However, Paul ehrlich’s idea was put into practice only in 
1975, when Köhler and Milstein’s study initiated the de-
velopment of monoclonal antibody technology. this tech-
nology makes it possible to produce not just a set of di-
verse immunoglobulin molecules (natural antibodies), but 
also a monospecific antibody focused on one specific anti-
gen (monoclonal antibody, MAb) in response to antigen-
driven immunization. this method is still the cornerstone 
of antibody reshaping. unfortunately, the first attempts 
to use mouse MAb for clinical purposes were not success-
ful and revealed the following, virtually insurmountable 
disadvantages of MAb: in some cases, its antibody affinity 
is lower than that of polyclonal antiserum; it has a high 
immunogenicity to humans and, as a consequence, is rap-
idly eliminated from the body; and it is unable to activate 
the complement system and cellular mechanisms of the 
immune response in a foreign environment. nevertheless, 
after three decades of battles and defeats, hopes and Pr 
blitzes, MAb proved to be a successful medicinal product 
from both the clinical and commercial standpoints (table 
1). the unique potential of immunoglobulins character-
ized by modular structures and functions related to other 
structural modules was realized, and the antibodies were 
modified for variable clinical applications thanks to the 
technologies of genetic engineering and transgenic ani-
mals. Depending on the practical task, researchers can reVIeWS
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directionally modify the molecular size, specificity, affin-
ity, and valency; they can decrease immunogenicity and 
refine pharmacokinetic properties and effector functions. 
Moreover, antibodies are obtained as recombinant-fused 
proteins which include other specific antibodies, cytok-
ines, protein toxins, radioisotopes, ferments, and fluores-
cent proteins. currently, about 30 antibody medicines are 
approved for clinical application, 89% of which are used in 
treating oncological and immunological diseases. Antibod-
ies are also used in treating cardiovascular, autoimmune, 
and infectious diseases (table 2). On the pharmaceutical 
market, antibodies come in second after vaccines in pro-
duction volume. By 2011, the sales volume of antibody 
medicines is predicted to increase to $21 billion (table 1). 
More than 85% of antibodies approved for clinical appli-
cation are products of antibody reshaping. the approved 
antibodies include chimeric, humanized, and human Mab; 
antibodies obtained using phage display; and genetically 
engineered antibody conjugates with cytokines and tox-
ins. Hundreds of antibody derivatives are still subject to 
Fig. 1. Natural antibodies and their fragments. Fab and (Fab)2 are antigen‑binding IgG fragments produced by papain and pepsin hydrolysis, respec‑
tively; Fc is the С-end part of IgG composed of СН2 and СН3 constant domains of heavy chains responsible for effector functions; Fv is the variable 
fragment composed of variable domains of light (VL) and heavy (VH) chains; scFv is the single‑chain variable fragment composed of VL and VH 
(conjugated by the gene engineering method); VHH is the nanoantibody, variable domain of cartilaginous fish and Camelidae antibodies containing 
only heavy chains; ‑S‑S‑ is the disulfide bond. The indicated linear dimensions of antibodies and their fragments were measured by force microscopy 
methods [2, 3]; hydrodynamic diameter dc was calculated by the Stokes-Einstein formula [4, 5].
Table 1. Commercial success of several MAb used in oncology [Deon‑
arain, 2008].
Commercial/
USAN1  
antibody name
Sales in 
2005–2006, 
US$, mln
Increase in sales 
relative to previ-
ous year, % 
Evaluation of 
sales market 
in 2011, US$, 
mln
rituxan©/
rituximab
3800 16 6300
Herceptin©/
trastuzumab
3100 82 4800
Avastin©/
bevacizumab
2400 77 7800
erbitux©/
cetuximab
1100 57 2100
1 Currently, the nomenclature of monoclonal antibodies and their frag‑
ments approved in the USA is used around the world (United States 
Adopted Names (USAN); www.ama‑assn.org), see Table 2.34 | ActA nAturAe |  № 1 2009
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Table 2. MAb medicines approved for clinical use and possible side effects.
 Application field
Commercial 
name USAN nomenclature name2 Antibody format Target
Application, action mechanism (↑ increase or ↓ 
decrease in effect)
Company and 
registration year
Possible side effects  
[http://www.i-sis.org.uk/WOFAMAD.php]
therapy of 
tumoral diseases
Avastin© Bevacizumab Humanized IgG1  VeGF
Intestine cancer.
Binding with ligand, antagonist.
Angiogenesis↓, metastasis↓.
Genentech, 2004
Gastro-intestinal perforations and wound disruption, occa-
sionally with a lethal outcome.
Bexxar© 131I-tositumomab Mouse 131I-IgG2a
 cD20 
 (B-cells)
non-Hodgkin lymphoma.
radioimmunotherapy, ADcc, cDc.
GlaxoSmithkline, 
2003
Hypersensitivity reactions, including anaphylaxis.
campath© Alemtuzumab Humanized IgG1  cD52 В-cell chronic lymphocyte leukemia.
Genzym/
Schering, 2001
Decrease of blood-forming functions of bone marrow, occa-
sionally serious to lethal outcome.
erbitux© cetuximab chimeric IgG1  eGFr
Metastatic cancer of intestine, head, and neck.
receptor antagonist. Apoptosis↑, chemo- and radiosen-
sitivity↑, proliferation↓, angiogenesis↓, metastasis↓.  
Imclone/Bristol-
Myers Squib, 2004
Anaphylactic reactions (3% of cases) (bronchial spasm, hoarse 
breath, hypotension), rarely lethal outcome (1 case in 1,000). 
Herceptin© trastuzumab IgG1 Her2
Her2-positive metastatic breast cancer. 
Proliferation↓, angiogenesis↓, chemosensitivity↑.
Genentech, 1997 cardiomyopathy.
Mylotarg© Gentuzumab ozogamicin
conjugate of humanized IgG4-
calicheamicin
cD33
cD33-positive acute myeloid leukemia.
cell intoxication due to induction of DnA breaks.
Wyeth pharma-
ceuticals, 2000
Heavy reactions of hypersensitivity, including anaphylaxis, 
hepatoxicity, and hematologic toxicity.
Prostascint© capromaab pentetate Mouse 111In-IgG1 
PSMA, prostate specific membrane 
antigen
Diagnostics of prostate cancer  cytogen, 1996
Anaphylactic or anaphylactoid shocks at single dosing. 
repeated dosing can cause danger to life due to serious sys-
tematic reactions of cardiovascular, respiratory, and nervous 
systems (shock, heart and respiratory arrest, paralysis).
rituxan© rituximab chimeric IgG1
cD20 
(B-cells)
non-Hodgkin lymphoma.
chemosensitivity, ADcc, cDc
Genentech/
Biogen, 1997
reaction to intravenous injection. Anaphylactic shock with 
lethal outcome. 
Vectibix© Panitumumab Human IgG2  eGFr (Her1)
Intestine cancer.
receptor antagonist. Apoptosis↑, chemo- and radiosen-
sitivity↑, proliferation↓, angiogenesis↓, metastasis↓.  
Amgen, 2006 no data
Zevalin© Ibritumomab tiuxetan Mouse 90Y-IgG1 
cD20
(B-cells)
non-Hodgkin lymphoma.
radioimmunotherapy, apoptosis↑
Biogen IDec, 2002
Scheme of treatment with the medicines includes rituxan© 
(see above).
transplantology
Orthoclone 
OKt3© Muromonab-cD3 Mouse IgG2a 
cD3  
(t-lymphocytes)
Prevention of acute rejection at renal transplantation. 
Blocking of Т-killers activity.
Ortho Biootech, 
1986
Anaphylactic or anaphylactoid shocks, including: cardiovas-
cular collapse, heart and respiratory arrest, convulsions, brain 
edema, blindness, and paralysis.
Simulect© Basiliximab chimeric IgG1  cD25
Prevention of acute rejection at renal transplantation. 
Blocking of IL-2r.
novartis, 1998
Heavy anaphylactic reactions (in 24 hours), including: 
hypotension, bronchial spasm, heart and respiratory arrest, 
pulmonary edema, fever, and loss of consciousness.
Zenapax© Daclizumab Humanized IgG1  cD25
Prevention of acute rejection at renal transplantation. 
Blocking of IL-2r.
roche, 1999
Heavy anaphylactic reactions (in 24 hours), including: hypoten-
sion, bronchial spasm, heart and respiratory arrest, arrhyth-
mia, pulmonary edema, fever, and loss of consciousness.
cardiovascular 
diseases
reoPro© Abciximab
F(ab)-chimeric fragment of 
IgG1  
complex of IIB-IIIA glycoproteins  
thromboprophylaxis. Antagonist of IIB-IIIA glyco-
proteins. 
centocor/elli 
Lilly, 1994
Indigestion, burning sensation, belching, pruritus, numbness, 
nervous system disorder, mental debility.
Monafram® F(ab’)2 fragment of mouse 
IgG1 
complex of IIB-IIIA glycoproteins 
thrombocytes
thromboprophylaxis at coronary angioplasty.
Antagonist of IIB-IIIA glycoproteins. 
Framon Ltd, 
russia, 2002
Bleeding, allergic reactions, thrombocytopenia (few cases of 
deep thrombocytopenia), immune response in 5–6% of cases
therapy of auto-
immune diseases
Humira© Adalimumab Human IgG1  tnFα
rheumatoid arthritis, psoriasis.
Blocking of tnFα activity, inflammation↓.
Abbottt 
Laboratories, 2002
tuberculosis, fungal invasion and other infections, acute 
myeloid leukemia.
raptiva© efalizumab Humanized IgG1  cD11a
Psoriasis.
Blocking of Т-lymphocytes activity.
Genentech/Xoma, 
2003 
Hemolytic anemia, serious infections including tuberculosis 
pneumonia and bacterial sepsis at antimicrobic therapy
remicade© Infliximab chimeric IgG1  tnFα
crohn’s disease, rheumatoid arthritis, inflammatory 
diseases.
Blocking of tnFα activity, inflammation↓.
centocor, 1998 tuberculosis infection, occasionally with lethal outcome.
tysabri©, 
Antegren© natalizumab Humanized IgG4 
α4 subunit of α4β1 and α4β7 
integrins
Multiple sclerosis.
Inhibition of immune cells migration to inflammatory 
tissue.
Biogen Idec/elan, 
2004
Sales were stopped in 2005. 
Progressive leukoencephalopathy in 1 case of extended 
medication use.
Xolair© Omalizumab Humanized IgG1  Ige
Allergic asthma.
Inhibits egress of Ige from mast cells.
Genentech, 2002 Appearance or recidive of cancer.
Others
Lucentis© ranibizumab
Humanized F(ab) fragment 
of IgG1  
VeGF
Age-related retina degeneration.
Blocking of angiogenesis.
Genentech/
novartis, 2006
Allergic reactions, intraocular inflammation, retinal hemor-
rhage.
Synagis© Palivizumab Humanized IgG1 
F-protein of respiratory syncytial 
virus
Infection prevention with respiratory syncytial virus. Medimmune, 1998
rarely acute hypersensitivity; repeated injection can cause (1 
case in 100 thousand) anaphylaxis.
1 Currently, the nomenclature of monoclonal antibodies and their fragments approved in the USA is used around the world (United States Adopted Names (USAN);  
www.ama‑assn.org), see Table 2.
2 Currently, nomenclature of monoclonal antibodies and their fragments approved in the USA is used in the whole world (United States Adopted Names (USAN);  
www.ama‑assn.org), see Table 2.reVIeWS
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Table 2. MAb medicines approved for clinical use and possible side effects.
 Application field
Commercial 
name USAN nomenclature name2 Antibody format Target
Application, action mechanism (↑ increase or ↓ 
decrease in effect)
Company and 
registration year
Possible side effects  
[http://www.i-sis.org.uk/WOFAMAD.php]
therapy of 
tumoral diseases
Avastin© Bevacizumab Humanized IgG1  VeGF
Intestine cancer.
Binding with ligand, antagonist.
Angiogenesis↓, metastasis↓.
Genentech, 2004
Gastro-intestinal perforations and wound disruption, occa-
sionally with a lethal outcome.
Bexxar© 131I-tositumomab Mouse 131I-IgG2a
 cD20 
 (B-cells)
non-Hodgkin lymphoma.
radioimmunotherapy, ADcc, cDc.
GlaxoSmithkline, 
2003
Hypersensitivity reactions, including anaphylaxis.
campath© Alemtuzumab Humanized IgG1  cD52 В-cell chronic lymphocyte leukemia.
Genzym/
Schering, 2001
Decrease of blood-forming functions of bone marrow, occa-
sionally serious to lethal outcome.
erbitux© cetuximab chimeric IgG1  eGFr
Metastatic cancer of intestine, head, and neck.
receptor antagonist. Apoptosis↑, chemo- and radiosen-
sitivity↑, proliferation↓, angiogenesis↓, metastasis↓.  
Imclone/Bristol-
Myers Squib, 2004
Anaphylactic reactions (3% of cases) (bronchial spasm, hoarse 
breath, hypotension), rarely lethal outcome (1 case in 1,000). 
Herceptin© trastuzumab IgG1 Her2
Her2-positive metastatic breast cancer. 
Proliferation↓, angiogenesis↓, chemosensitivity↑.
Genentech, 1997 cardiomyopathy.
Mylotarg© Gentuzumab ozogamicin
conjugate of humanized IgG4-
calicheamicin
cD33
cD33-positive acute myeloid leukemia.
cell intoxication due to induction of DnA breaks.
Wyeth pharma-
ceuticals, 2000
Heavy reactions of hypersensitivity, including anaphylaxis, 
hepatoxicity, and hematologic toxicity.
Prostascint© capromaab pentetate Mouse 111In-IgG1 
PSMA, prostate specific membrane 
antigen
Diagnostics of prostate cancer  cytogen, 1996
Anaphylactic or anaphylactoid shocks at single dosing. 
repeated dosing can cause danger to life due to serious sys-
tematic reactions of cardiovascular, respiratory, and nervous 
systems (shock, heart and respiratory arrest, paralysis).
rituxan© rituximab chimeric IgG1
cD20 
(B-cells)
non-Hodgkin lymphoma.
chemosensitivity, ADcc, cDc
Genentech/
Biogen, 1997
reaction to intravenous injection. Anaphylactic shock with 
lethal outcome. 
Vectibix© Panitumumab Human IgG2  eGFr (Her1)
Intestine cancer.
receptor antagonist. Apoptosis↑, chemo- and radiosen-
sitivity↑, proliferation↓, angiogenesis↓, metastasis↓.  
Amgen, 2006 no data
Zevalin© Ibritumomab tiuxetan Mouse 90Y-IgG1 
cD20
(B-cells)
non-Hodgkin lymphoma.
radioimmunotherapy, apoptosis↑
Biogen IDec, 2002
Scheme of treatment with the medicines includes rituxan© 
(see above).
transplantology
Orthoclone 
OKt3© Muromonab-cD3 Mouse IgG2a 
cD3  
(t-lymphocytes)
Prevention of acute rejection at renal transplantation. 
Blocking of Т-killers activity.
Ortho Biootech, 
1986
Anaphylactic or anaphylactoid shocks, including: cardiovas-
cular collapse, heart and respiratory arrest, convulsions, brain 
edema, blindness, and paralysis.
Simulect© Basiliximab chimeric IgG1  cD25
Prevention of acute rejection at renal transplantation. 
Blocking of IL-2r.
novartis, 1998
Heavy anaphylactic reactions (in 24 hours), including: 
hypotension, bronchial spasm, heart and respiratory arrest, 
pulmonary edema, fever, and loss of consciousness.
Zenapax© Daclizumab Humanized IgG1  cD25
Prevention of acute rejection at renal transplantation. 
Blocking of IL-2r.
roche, 1999
Heavy anaphylactic reactions (in 24 hours), including: hypoten-
sion, bronchial spasm, heart and respiratory arrest, arrhyth-
mia, pulmonary edema, fever, and loss of consciousness.
cardiovascular 
diseases
reoPro© Abciximab
F(ab)-chimeric fragment of 
IgG1  
complex of IIB-IIIA glycoproteins  
thromboprophylaxis. Antagonist of IIB-IIIA glyco-
proteins. 
centocor/elli 
Lilly, 1994
Indigestion, burning sensation, belching, pruritus, numbness, 
nervous system disorder, mental debility.
Monafram® F(ab’)2 fragment of mouse 
IgG1 
complex of IIB-IIIA glycoproteins 
thrombocytes
thromboprophylaxis at coronary angioplasty.
Antagonist of IIB-IIIA glycoproteins. 
Framon Ltd, 
russia, 2002
Bleeding, allergic reactions, thrombocytopenia (few cases of 
deep thrombocytopenia), immune response in 5–6% of cases
therapy of auto-
immune diseases
Humira© Adalimumab Human IgG1  tnFα
rheumatoid arthritis, psoriasis.
Blocking of tnFα activity, inflammation↓.
Abbottt 
Laboratories, 2002
tuberculosis, fungal invasion and other infections, acute 
myeloid leukemia.
raptiva© efalizumab Humanized IgG1  cD11a
Psoriasis.
Blocking of Т-lymphocytes activity.
Genentech/Xoma, 
2003 
Hemolytic anemia, serious infections including tuberculosis 
pneumonia and bacterial sepsis at antimicrobic therapy
remicade© Infliximab chimeric IgG1  tnFα
crohn’s disease, rheumatoid arthritis, inflammatory 
diseases.
Blocking of tnFα activity, inflammation↓.
centocor, 1998 tuberculosis infection, occasionally with lethal outcome.
tysabri©, 
Antegren© natalizumab Humanized IgG4 
α4 subunit of α4β1 and α4β7 
integrins
Multiple sclerosis.
Inhibition of immune cells migration to inflammatory 
tissue.
Biogen Idec/elan, 
2004
Sales were stopped in 2005. 
Progressive leukoencephalopathy in 1 case of extended 
medication use.
Xolair© Omalizumab Humanized IgG1  Ige
Allergic asthma.
Inhibits egress of Ige from mast cells.
Genentech, 2002 Appearance or recidive of cancer.
Others
Lucentis© ranibizumab
Humanized F(ab) fragment 
of IgG1  
VeGF
Age-related retina degeneration.
Blocking of angiogenesis.
Genentech/
novartis, 2006
Allergic reactions, intraocular inflammation, retinal hemor-
rhage.
Synagis© Palivizumab Humanized IgG1 
F-protein of respiratory syncytial 
virus
Infection prevention with respiratory syncytial virus. Medimmune, 1998
rarely acute hypersensitivity; repeated injection can cause (1 
case in 100 thousand) anaphylaxis.
1 Currently, the nomenclature of monoclonal antibodies and their fragments approved in the USA is used around the world (United States Adopted Names (USAN);  
www.ama‑assn.org), see Table 2.
2 Currently, nomenclature of monoclonal antibodies and their fragments approved in the USA is used in the whole world (United States Adopted Names (USAN);  
www.ama‑assn.org), see Table 2.36 | ActA nAturAe |  № 1 2009
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clinical testing, including synthetic antibodies produced 
by gene engineering: bispecific antibodies; single-chain 
full-sized antibodies; different variants of truncated anti-
bodies, including dimers and monomers of Fab fragments, 
scFv-fragments (single-chain mini-antibodies), single-do-
main antibodies (nanoantibodies), etc. Different technolo-
gies that make it possible to modify immunoglobulin mol-
ecules for certain clinical purposes are considered. this 
review is focused on antibody reshaping for the treatment 
and detection of oncological diseases, because this sphere 
is in particular need of these medicines. 
1 . THE STRuCTuRE OF A NATuRAL ANTIBODy AND wHy 
IT NEEDS MODIFICATION FOR CLINICAL PuRPOSES .
Antibodies, also known as immunoglobulins (IgG), are 
high-avid molecules which can detect and eliminate foreign 
antigens from the human organism. Most mammal antibod-
ies have similar structures and are bivalent multidomain 
proteins with two antigen-binding sites (see, for example, 
human G immunoglobulin (IgG), Fig. 1). this compound Y-
shaped molecular complex consists of two identical heavy 
(~50 kDa) and two identical light (~25 kDa) chains. Four 
inter-domain disulfide bonds provide stable conditions for 
the whole molecular complex. Globular structural immu-
noglobulin domains with a characteristic β-folded struc-
ture are stabilized by intradomain disulfide bonds and are 
subdivided into variable (V) and constant (c) domains. n-
tail domains of light and heavy chains (VL and VH vari-
able domains) vary significantly for different antibodies, 
while the remaining part of the polypeptide chains (СL and 
cН constant domains) varies for different antibody classes 
(and within one antibody class, depending on the species). 
the structural domains of immunoglobulin are isolated in 
space and perform different functions in the immune re-
sponse process. 
each antibody is characterized by a private specificity 
and a high affinity (КD 10-8–10-11 M) to its antigen, which is 
provided by the complementarity of the antigen-binding 
site to the definite antigen molecule site (epitope). each an-
tigen-binding site is composed of two variable domains—
VH and VL—which are referred to as heavy and light 
chains of immunoglobulin, respectively. each variable do-
main contains three complementarity determined regions 
(cDr). the ability of antibodies to bind two antigens si-
multaneously significantly increases the functional affin-
ity (avidity) of immunoglobulins and the retention time on 
the surface cell receptors and other polyvalent antigens. 
In all, humans are known to have five classes of antibodies 
(IgM, IgG, Ige, IgD, and IgA). not long ago, some animals 
(camel, llama, and shark) were revealed to have nonclassic 
antibodies without any light chains and with two antigen-
binding sites, each of which is made up of only one heavy 
Fig. 2. Interaction Pattern of 
Unloaded Antibodies and Target 
Cell. (1) Antibodies can cause 
apoptosis or block the prolifera‑
tion of target cells, binding with 
membrane antigens on their sur‑
face (membrane raft mechanism) 
[6]. (2) Antibody‑dependent 
cellular cytotoxicity (ADCC). 
Killer cells carrying receptors of 
IgG FcγRI (CD16), FcγRII (CD32), 
FcγIII (CD64) constant domains 
(natural killers, killers activated 
by lymphokines, macrophages, 
and phagocytes) and receptors 
of IgE FcεRI and FcεRII (CD23) 
constant domains (acidocytes) 
on their surface attack the target 
cell, whose surface antigens 
were bound with antibodies. 
(3) Complement‑dependent 
cytotoxicity (CDC). Antibod‑
ies conjugated in pairs bind to 
protein С1q complex, causing 
a cascade of reactions of the 
complement system, which leads 
to membrane destruction. Some 
products of this reaction cascade 
involve immune cells or cause 
allergic shock.  reVIeWS
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chain variable domain. the camel’s variable domains were 
called “nanobodies” (Fig. 1).
the constant part of immunoglobulin consists of one 
light chain (cL) domain and three or four (depending on 
the class) heavy chain (cH) domains. Hydrophobic sites on 
the boundary of СН1 and СН2 domains remain mobile and 
form a link region, which provides the displacement and 
rotation of Fb-fragments. the heavy chain constant do-
mains are, as a rule, glycosylated. the type of glycosylation 
varies significantly for different species and influences the 
immunoglobulin effector functions. Moreover, heteroge-
neous glycosylation is characteristic for the antibodies of 
one isotype within one species.
the IgG constant domain contains binding sites with 
protein of the С1q complement system and Fc-fragment 
cell receptors (Fcγr), which mediate the effector (second-
ary) functions of immunoglobulins, i.e., their ability to kill 
target cells, activating the mechanisms of antibody-depen-
dent cellular cytotoxicity (ADcc) and complement-depen-
dent cytotoxicity (cDc). the ability of IgG and IgM to bind 
to neonatal Fc-receptor (Fcrn) plays a very important role 
in controlling the antibody level in the blood serum. Hence, 
in the immune response process, an organism produces a 
complex set of heterogeneous molecules, which can include 
several cell mechanisms and a series of reactions for elimi-
nating foreign antigens. 
Modern antibody reshaping is based on the monoclonal 
antibody technology put forth by Köhler and Milstein in 
1975 [7]. this method involves the fusion (hybridization) of 
immune lymphocytes (splenicytes) which synthesize anti-
bodies of the required specificity with the immortal my-
eloma cell line. the cell line obtained (hybridome) secretes 
monoclonal antibodies (MAb), i.e., antibodies of the same 
species, specific to the antigen used for immunization. the 
in vitro cultivation of hybridome or the propagation sim-
ilarly to ascite in a mouse makes it possible to have con-
stant sources of antibodies with definite specificities. the 
fusion of hybridomes characterized by various specificities 
enables one to obtain so-called quadroms, which produce— 
along with the primary MAb—monoclonal bispecific anti-
bodies capable of binding with two different antigens. 
the introduction of monoclonal antibody technology 
led to great progress in using antibodies for both research 
and practical purposes (in vitro diagnostics). However, the 
hopes for creating specific and highly efficient anticancer 
drugs on the basis of MAb and their conjugates with active 
agents and for the rapid replacement of serum-derived 
vaccines with the MAb medicines, which would eliminate 
pathogenic microorganisms and toxins, were snuffed out. 
the idea of using MAb for the delivery of radioactive iso-
topes to target cells proved imperfect as well. It emerged 
that MAb have some properties which make them ineffec-
tive and dangerous for clinical use. At the first stages, in-
dividual MAb produced from a hybridome pool were often 
specified by a less efficient interaction with antigen than 
polyclonal antiserum dilution. the reason for this is the in-
teraction between individual MAb and the sole antigenic 
epitope and, probably, the partial inactivation of antibod-
ies in the release process. Full-size MAb have non-optimal 
pharmacokinetic properties for application as targeting 
molecules. As foreign proteins, mouse MAb are subject to 
rapid catabolism. Moreover, they have almost no interac-
tion with the Fcrn receptor, which is responsible for the 
recirculation of immunoglobulins from lysosomes, which 
speeds up the MAb removal from the blood flow. On the 
contrary, full-size MAb circulate in the blood flow for up 
to 2 weeks. Due to their high molecular weight (150 kDa), 
immunoglobulins are slowly distributed in the organism, 
have poor penetration ability, and are not cleansed from 
the body through the kidneys. the xenogenic nature of 
MAb impedes the activation of a complement system and 
the cell mechanisms of foreign antigen elimination (ADcc 
and cDc) due to the poor identification of the mouse MAb 
by Fc-receptors of human immune system cells. the high 
immunogenicity of mouse MAb is dangerous for a human 
being and cannot be used for clinical purposes due to the 
risk of hyperimmune reaction formation. Serious side ef-
fects related to the nature of the toxin attached were also 
noted when the first generation of immunotoxins was used. 
It ought to be noted that the MAb medicines successfully 
used in medical treatment today have dangerous side ef-
fects (table 2).
the experience and new knowledge about the mecha-
nism of interaction between antibodies and target mole-
cules were gained through trial and error. It appears that 
some clinical cases require MAb modifications, often mutu-
ally antithetical. the technologies of gene engineering and 
transgenic animals, along with monoclonal antibody tech-
nology, made the greatest contribution to antibody reshap-
ing. Let’s provide some insight into the major directions of 
antibody engineering for clinical use. currently, the anti-
body medicines approved by the unites States system (uS 
Adopted names, www.ama-assn.org) are used (table 3). 
2 . TRuNCATED ANTIBODy FRAGMENTS AND ALTERNATIVE 
FRAMEwORK PROTEINS wITH SPECIFIC ANTIGEN BINDING
Originally, the most attractive property of antibodies in 
terms of the “magic bullet” construction was their specif-
ic binding with the antigen, which was assumed to allow 
the delivery of an active agent (for instance, a radioactive 
isotope) to a target molecule. the governing factors which 
would provide the efficiency of this delivery are the affin-
ity and specificity of the antibody targeted to the antigen, 
as well as its physicochemical properties, such as valency, 
surface charge, and size [8, 9].
the specificity of an antibody constructed for thera-
peutic use depends on selecting the appropriate target 
molecule. the MAb approved for clinical use are directed 
against 15 targets, most of which are surface cellular anti-
gens, including such widespread cancer markers as Her1, 
Her2/neu, and PSMA (prostate specific membrane anti-
gen) (table 2). the last decade was characterized by gre-
at progress in understanding the mechanism of antibody 
action and in developing new target molecules for treating 
oncological, autoimmune, infection, and cardiovascular de-
seases. 
Five groups of potential target molecules for antibod-
ies in cancer treatment have been pointed out in recent 
reviews: cancer cells inside solid tumors, which are less 
treatable; diffusive cancerous cells (leukemia); the stroma 38 | ActA nAturAe |  № 1 2009
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associated with the tumor (fibroblasts); and blood vessels 
associated with the tumor and vascular endothelial growth 
factors (VeGF) [10, 11]. Additional target molecules can 
appear in response to blocking surface receptors [12] or 
inducing cancer cells under the action of a medical agent 
[13]. 
the affinity of antibodies used in therapy today is with-
in the nanomolecular concentrations (from 10-8 to 10-10 М), 
which are optimal for solving most problems. Increasing 
the antibody affinity to 10-11 М significantly decreases both 
its ability to penetrate the tumor and its targeting selectiv-
ity [14].  
the size of the therapeutic antibody molecules is an im-
portant factor, because it determines the possibility and 
rate of renal excretion. the time of the renal half-excretion 
of protein correlates with the molecular size: the limit of 
glomerular filtration is estimated at 60–65 kDa [15]. the 
full-size IgG molecules (~150 kDa) (Fig. 1) are too large 
and cannot be excreted through the kidneys. In contrast, 
the scFv-fragments (~30 kDa) (Fig. 1) are characterized by 
0.5–2 hours of half-removal period and readily leave the 
organism [16]. the monomeric Fab-fragments (48 kDa) 
hold an intermediate position, with 14–15.5 hours of half-
removal time [16, 17]. 
the optimal surface charge for therapeutic antibodies 
is the interval of their isoelectric points from 5 to 9. An in-
crease in the positive or negative charge complicates the 
antibody binding with the target cells [18].  
the valency of the recombinant antibody targeted on 
the antigen plays a very important role in retaining MAb 
in the target cells. Most natural mammal antibodies are 
bivalent. the ability to simultaneously bind two antigens 
significantly increases the functional affinity, or avidity, 
of immunoglobulins and provides the long-term retention 
of antibodies on the cell surface receptors or polyvalent 
antigens. this property is used in the wild: tetra- and de-
cavalent complexes of IgA and IgM are characterized by a 
higher affinity to the multipoint binding of polyvalent anti-
bodies and can protect against natural polyvalent antigens, 
such as pathogenic microorganisms, more efficiently. 
Table 3. USAN nomenclature of therapeutic medicines with antibodies and their fragments (United States Adopted Names; http://www.ama‑assn.org/"www.ama‑assn.org).
Prefix Disease or target Antibody origin Suffix examples
Appropriate 
syllable(s)  
different 
from those 
used earlier
vir - virus
bac - bacterial
lim – immune system
les - infection
cir – cardiovascular
fung – fungal
ner – nervous system
kin – interleukin
mul – skeletomuscular system
os – bones
toxa – toxins
anibi – angiogenesis
tumors:
col – large guts
mel – melanoma
mar – lacteal gland
got – spermary
gov – ovary
pro – prostate gland
tum - different
u – human being
o – mouse 
a – rat 
e – hamster 
i – primate 
axo – rat/mouse 
xi – chimera 
zu – humanized 
xizu – combination of chi-
meric and humanized chains 
mab
tras tu zu mab
Trastuzumab (Herceptin©) –  
anti-tumor humanized MAb 
ab ci xi mab
Abciximab (reoPro©) –  
chimeric MAb for thromboprophylaxis 
r anibi zu mab
Ranibizumab (Lucentis©) –  
humanized MAb to block angiogenesis 
To create new designation, it is essential:
To choose the appropriate syllable(s) different from any used earlier and to put it (them) at the beginning of a word;
To add syllables in the following order: disease class (tumor type) or target, source of origin, suffix “mab”;
To simplify pronunciation, the last consonant in the syllable designating the target may be omitted.reVIeWS
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Hence, using antibodies as targeting components for the 
delivery of diagnostic and therapeutic agents of, primarily, 
radioactive isotopes and as specific blockers of pathogenic 
processes required the elimination of their effector func-
tions and a cardinal modification of their physicochemical 
properties. 
the first truncated fragments of antibodies—monomer-
ic Fab and dimeric (Fab)2 (Fig. 1)—meant for use in radio-
immunotherapy were produced by processing intact IgG 
with such proteolytic enzymes as papain and pepsin (Fig. 1). 
these fragments are  absent in the Fc domain, which me-
diates the IgG effector properties that are undesirable in 
the current situation. Moreover, the considered fragments 
are not capable of recirculating from lysosomes, which 
causes the dose-limiting myelotoxicity and nonspecific ra-
dioactive background to decrease in comparison with the 
full-size IgG. However, the fragments obtained retain an-
tigen-binding properties that are comparable with those 
of the parent antibodies. examples of the therapeutic use 
of the monomeric Fab-fragment include reoPro© antiag-
gregant (Abciximab) and its russian analogue, Monafram® 
[19], which are applied in cardiosurgery for thrombosis 
prevention, as well as an angiogenesis blocker—Lucentis©( 
ranibizumab)—used for treating age-related retina degen-
eration (table 2). Because of its diminished size, Lucentis©( 
ranibizumab) readily penetrates into the inner eye cov-
er, unlike full-size antibodies, making it ideal for clinical 
application [17]. the main disadvantage of the enzymatic 
method of antibody fragment production is the compli-
cated purification of the target product. Moreover, further 
modification of the antibody’s physicochemical properties 
is possible only by chemical methods. Furthermore, the 
first generation of Fab-fragments was of mouse origin and 
characterized by high immunogenicity.  
Developing genetic engineering methods made it pos-
sible to simplify the preparation of truncated antibody de-
rivatives. recombinant antibodies, so called single-chain 
variable fragments (scFv) (Fig. 1), are coded by one gene 
and contain only one antigen-binding site, which consists 
of variable domains of light (VL) and heavy (VH) chains 
connected by an elastic peptide linker [20] (Fig. 1). these 
scFv-fragments are monovalent and are often specified by 
a lower affinity than the primary one. their rapid remov-
al from the organism and homogenic focus on the target 
makes them more appropriate for delivering radioactive 
isotopes than the parent full-size IgG. Other very impor-
tant advantages of single-chain antibodies are as follows: 
their compatibility with bacterial expression systems, their 
reduced immunogenicity, and their absence of effector 
functions. nevertheless, the monovalent scFv-fragments 
never gained universal currency in medical practice, be-
cause even a high-affinity but a monovalent binding with 
the antigen on the cell’s surface does not provide long re-
tention and leads to the rapid dissociation of antibody. 
cloning single-chain antibodies retaining antigen-bind-
ing functions had significant consequences. From then on, 
the technologies for creating synthetic antibodies of almost 
any specificity were quickly climbing to new heights. Di-
verse collections (libraries) of recombinant antibody frag-
ments were designed, new methods which could increase 
their diversity were offered, and technologies which made 
it possible to increase the affinity of antibodies and effi-
ciently select new variants were developed [21, 22]. the se-
lection platforms for immunoglobulin libraries were devel-
oped on the basis of phage, ferment, and ribosomal displays 
[23]. nonclassical antibodies of cartilaginous fish and ani-
mals of the camelidae genus (camel and llama), containing 
only heavy chains, were the perspective source for anti-
gen-binding fragments with uncommon properties (Fig. 1). 
An antigen-binding site of such antibodies was formed by 
the sole variable domain, which is characterized by good 
solubility, high stability, and the ability to bind with diffi-
cult-to-access antigens [24, 25].
that period was also marked by the intensive develop-
ment of molecular constructions—alternatives to the bind-
ing domains of antibodies—which were called scaffolds in 
english-language scientific literature. this term was of-
fered by A. Plyuktun [26] for designating a protein carcass 
or framework bearing altered amino-acid residues or small 
sequences, which provided different protein variants with 
various functions, commonly, the possibility of effective 
binding with specific target molecules. the word scaffold 
is translated into russian as a construction for capital pun-
ishment or as construction trestles. “construction trestles” 
is the implied meaning, but it is hardly possible to use this 
phrase in the context of protein engineering. therefore, we 
offer the terms framework protein or framework peptide 
along with the english calque scaffold.
typical natural framework proteins or scaffolds are an-
tibodies or t-cell receptors. there are many other natural 
and synthetic framework proteins, for instance, affibody, 
peptabody, ankyrin repeats, and lipokalins [26]. Developing 
alternative framework compounds is a perspective direc-
tion in research for creating new compounds to selective-
ly bind to target molecules and cells. new compounds are 
meant for biomedical use and are appropriate for robotic 
technologies and the construction of supramolecular nanos-
tructures. these facts are confirmed by the creation of the 
ProteomeBinders Association in europe, which is focused 
on thoroughly studying human proteome using high-affin-
ity reagents [27].   
3 . GENE ENGINEERING TECHNOLOGIES FOR OPTIMIzING 
BIODISTRIBuTION AND PHARMACOKINETICS .
A wide range of theoretical and experimental data testifies 
to the fact that the simplest method to overcome the im-
perfection of the recombinant single-chain Fv-fragments 
is a return to multivalency, which is a primary character-
istic property of antibodies. Indeed, every effort was spent 
to construct multimeric formats of truncated antibodies in 
order to optimize their pharmacokinetic properties and to 
improve the biodistribution of the active agents delivered 
by antibodies. currently, a wide variety of such construc-
tions is subject to clinical testing [28, 29]. 
In the past decade, a wide range of methods was de-
veloped in engineering multivalent antibodies; they are 
described in detail in our review [9]. the valency of the 
constructed multivalent derivatives, i.e., the number of 
antigen-binding units, may vary from 2–10. the offered 
strategies are based on the chemical conjugation of anti-40 | ActA nAturAe |  № 1 2009
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body fragments, the use of self-associating peptides, and 
the phenomenon of domain shuffling when two antibod-
ies of different specificities are mixed. Antibodies, both bi-
valent tandem and bispecific are obtained by linear gene 
fusion. using heterodimerization modules, including the 
streptavidin-biotin system, the barnase–barstar module 
[30, 31], and the “knob-and-holes” [32] and “dock and lock” 
[33, 34] methods, is more universal. each strategy has ad-
vantages and disadvantages, but none of them is univer-
sal. the systematization and comparative analysis of the 
experimental data on the pharmacokinetics of multiva-
lent antibody derivatives of different formats focused on 
Her2/neu and ceA cancer markers and on angiogenesis 
markers, such as the eD-B domain of fibronectin, showed 
that pharmacokinetic characteristics and biodistribution 
are significantly improved when monovalent antibodies are 
replaced with bivalent (multivalent) varieties [9].  
One more important method of varying the MAb phar-
macokinetic characteristics is a delicate site-specific modi-
fication of the constant domain depending on certain ap-
plications of the immunoglobulin constructed. neonatal or 
so-called “salvage” Fc-receptors (Fcrn) perform the follow-
ing important functions in an organism: they transport IgG 
through epithelial and endothelial barriers, they transmit 
immunoglobulins from mother to child, and they protect 
IgG and albumin against catabolism in lysosomes of vascu-
Fig. 3. Modification of mouse monoclonal antibodies (MAb) for clinical application. The following MAb fragments produced by gene engineering 
are considered: (1) single chain antibodies (scFv or mini‑antibodies) of different specificity and composed of VL‑ and VH‑domains bound by peptide 
linker; (2) bispecific mini‑antibody; (3) dimeric mini‑antibody; (4, 5) dimmer and trimer of mini‑antibody bound by the barnase–barstar module; (6) 
conjugate of mini‑antibody with bioactive agent produced by the gene engineering method; (13) human MAb with modified constant domains; (14) 
human MAb with modified carbohydrate component (15). Legends of antibodies and their fragments are as in Fig. 1; hypervariable sites of variable 
domains (CDR) are indicated with black color; mouse antibodies and fragments, with dark gray; human antibodies and fragments, with light grey; vari‑
able domains of different specificity (1–5) and modified constant domains (13) are indicated with hatching. White semicircle and black triangle denote 
barnase and barstar, respectively. А denotes the bioactive component (radioactive isotope, toxin, ferment, fluorescent protein, etc.).reVIeWS
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lar endothelial [35]. Fcrn is characterized by a high affinity 
to IgG at рН 6.0 and does not bind with it at рН 7.2. Hence, 
the mechanism of IgG prevention against catabolism is 
based on the binding of Fcrn with antibodies in lysosomes 
at рН 6.0 and returning to the blood flow [36]. Directed mu-
tagenesis of the Fc-fragment makes it possible to produce 
different variants of antibodies, randomly changing the 
time of their half-life in the blood flow [37]. replacing key 
amino-acid residues in the constant domain sites of mouse 
anticancer antibodies that are involved in the interaction 
with Fcrn allowed several mutants to be prepared with a 
half-life time from 8 to 80 hours in the mouse's organism. 
the same indicator is ~12 days for wildlife antibodies [38]. 
these antibodies are readily removed from the organism, 
which is of critical importance for radioimmuno therapy 
and improves the resolution when the scintigraphy meth-
ods are used. On the other hand, mutant antibodies with a 
higher affinity to binding with Fcrn at pH 6.0 are specified 
by a longer half-life in the organism [39]. Increasing the 
circulation time is important when using therapeutic anti-
bodies to treat infectious diseases or neutralize antibodies 
for treating acute intoxications. For instance, injecting tri-
ple mutation M252Y/S254t/t256e into the MAb constant 
domain specific to the respiratory syncytial virus increased 
their binding by ten times at pH6.0 with Fcrn of a human 
being and a crab-eating macaque (Macaca fascicularis). At 
the same time, mutant MAb are readily separated from 
antibodies at рН 7.4. Investigating the pharmacokinetic 
properties of mutant MAb on the basis of a primate model 
showed that the lengths of both their half-life in the blood 
flow and accumulation in the lungs increased 4 times [40]. It 
ought to be noted that mutagenesis of the constant domain 
amino-acid residues responsible for binding with Fcrn 
commonly does not influence other effector properties of 
antibodies. Hence, directed alteration of the Fcrn-binding 
sites allows the control of the pharmacokinetic properties 
of MAb constructed for different purposes. Moreover, cre-
ating peptide antagonists, which block the Fcrn receptor, 
may be done to decrease the level of pathogenic IgG in the 
organism, which is one more method of autoimmune dis-
ease treatment [41]. 
An alternative method to improve the pharmacoki-
netics and biodistribution of mini-antibody derivatives is 
adding polyethyleneglycol [42] and albumin [43], which 
would increase the molecular weight of the compound 
and, respectively, decrease renal excretion. It is quite pos-
sible that when albumin is added, additional recirculation 
mechanisms mediated by the neonatal receptor are acti-
vated [44].  
4 . THE REDuCTION IN THE IMMuNOGENICITy OF 
MONOCLONAL ANTIBODIES (HuMANIzATION) .
One of the first problems arising in the course of creating 
antibodies for clinical purposes is the high immunogenicity 
of MAb, which is xenogenic for a human being. the human 
anti-mouse antibodies response (HAMA) causes serious sys-
tematic reactions in the human organism up to allergic shock 
(table 2). using gene engineering methods allowed the par-
tial replacement of the mouse MAb immunogenic sites with 
the corresponding fragments of human antibodies. 
In chimeric MAb [45] (Fig. 3), all constant domains of 
mouse antibodies are replaced with constant domains of 
human immunoglobulin. In humanized MAb (Fig. 3), only 
hypervariable sites responsible for complementary in-
teraction with antigen (cDr) are of mouse origin. Mono-
genic constructions of humanized antibodies are produced 
by gene engineering methods as well [46]. currently, pure 
mouse antibodies are applied in small doses only in radi-
oimmunotherapy, due to the necessity of rapid excretion 
from the blood flow (Bexxar© and Zevalin© medicines in ta-
ble 2). 
More complex technologies were developed to obtain 
pure human MAb (Fig. 3). Screening antibody scFv or Fab-
fragments of the desired specificity from the combinatorial 
libraries (phage, ribosome, and ferment displays) with the 
following reconstruction of full-size human immunoglob-
ulins from them does not require preliminary immuniza-
tion. the Adalimumab (Humira©) medicine widely used 
in treating autoimmune diseases was initially obtained as 
a scFv-fragment by the cambridge Antibody technology 
(MedImmune) and then restored to the formation of an an-
tibody [47]. Pure human MAb are also created in transgenic 
mice with the expressing genes of human immunoglobulins. 
the technology involves replacing mouse IgG gene locuses 
with their corresponding human genome sites. One exam-
ple is Panitumumab (Vectibix©), specific to eGFr, made 
by HuMouse technology (Abgenix).
currently, this sphere is being actively developed, and 
all the many methods used for antibody humanization may 
be conditionally subdivided into rational and empiric [48]. 
the rational methods involve a so-called design cycle: gen-
erate a few variants based on data on the structure of the 
antibody and its gene, followed by analyzing the variants, 
and then selecting the best variant. the rational methods 
include the following procedures: grafting hypervariable 
sites of the mouse MAb responsible for the complemen-
tarity of interaction (cDr-grafting) or only 20–30% of 
those responsible for specificity (SDr-grafting) into the 
framework of the human immunoglobulin [49]; resurfac-
ing mouse MAb to make it similar to the human immu-
noglobulin surface; and superhumanization based on the 
detection and elimination of potential epitopes from the 
mouse immunoglobulin molecule for a major complex of 
histocompatibility and t-cells, i.e., human string content 
optimization [50]. recently, the single-domain antibodies of 
a camel (nanoantibodies) (Fig. 1), which are characterized 
by high stability, technological effectiveness, and the abil-
ity to bind hard-to-access antigens, have drawn the atten-
tion of researchers. the general strategy of humanization 
was developed to apply those nanoantibodies for clinical 
purposes [51]. researchers revealed amino-acid residues 
which determine the distinctions of nanoantibodies and 
the corresponding heavy chain variable domain of human 
IgG. then, nanoantibodies taken from the representative 
library were humanized in the course of the sequential re-
placement of several sites in the molecule. After that pro-
cedure, nanoantibodies remained stable enough and kept 
their primary affinity. 
In contrast to the rational methods, empiric methods of 
humanization are based on the creation of large combina-42 | ActA nAturAe |  № 1 2009
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torial libraries [21, 22] and selecting the required variants 
using such processing technologies as phage, ferment or 
ribosomal displays, or high throughput screening methods 
[23]. these methods may be applied mostly to single-chain 
antibodies (scFv), which, when needed, may be trans-
formed into monogenic MAb [46] (Fig. 3, 8) by fusion with 
the Fc constant domain and dimerization or they may be 
reconstructed into a full-sized antibody with a classical 
structure. 
As a rule, both rational and empiric methods comple-
ment each other. currently, about 40 humanized and hu-
man MAb obtained by new selection methods for cancer 
treatment are undergoing the last stages of clinical test-
ing [47]. the humanization of therapeutic antibodies not 
only weakened the dangerous side effects, but also allowed 
more complete use of the powerful potential of MAb, i.e., 
the involvement of effector functions. 
5 . THE OPTIMIzATION OF ANTIBODy EFFECTOR FuNCTIONS . 
Antibodies bound to the surface of the target cell can cause 
its death by triggering the ADcc and cDc mechanisms (see 
above) (Fig. 2). Far from all clinical applications of Mab find 
these mechanisms useful. For instance, the MAb effector 
functions are not required for the directed delivery of radio-
immunoisotopes or blocking transplant rejection; moreover, 
they can cause dangerous complications. In other cases, the 
action of MAb may be intensified with the aid of killer cells. 
One such method was creating bispecific MAb, which at-
tracted cytotoxic t-lymphocytes to the target cells (see Sec-
tion 6). Moreover, in recent years researchers have detected 
a wide range of immunocyte receptors responsible for the 
interaction with antibodies and determining the role of IgG 
sites in this interaction. recent investigations have showed 
that the efficiency of a therapeutic antibody depends on its 
affinity to FcγrIIIа (cD16) and FcγrIIа (cD32), which is 
characteristic for the activating receptors of most killer cells. 
It became apparent that the reaction of a patient to treat-
ment by MAb medicines depends on his phenotype. Patients 
with FcγrIIIа-158 V/V and FcγrIIа-131 Н/Н phenotypes 
are at an advantage when being treated for follicular and 
non-Hodgkin lymphoma with rituxan© (rituximab) [52]. 
Analogous results were obtained when breast cancer was 
treated by MAb Herceptin© (trastuzumab) [53]. On the other 
hand, a therapeutic antibody can bind to a Fcr receptor on 
non-toxic cells (thrombocytes and B-cells), which are able to 
inhibit the activation of effector killer cells (for instance, the 
FcγrIIb receptor on macrophages). experiments on animals 
show that the FcγrII inhibitor isoform decreases the thera-
peutic effect of humanized Herceptin© (trastuzumab) [54]. 
the presented data testify to the fact that, at the current 
stage of gene engineering, it is essential to optimize the ef-
fector functions of the antibody depending on the sphere of 
application in order to increase the efficiency of the thera-
peutic treatment. 
It is also necessary to mention the constructions where 
a constant part of immunoglobulin is used in combination 
with targeting peptides (instead of the IGG antigen-bind-
ing sites) [55] or with monomeric and dimeric cytokines to 
improve pharmacokinetics and protect against degradation 
[56].
there are several methods to optimize the antibody's 
effector functions. to deactivate these functions, scien-
tists use different variants of truncated antibodies de-
pleted in the constant domains responsible for binding 
to the clq component and killer cells (see Section 3). ex-
amples of truncated antibodies are reoPro© (Abciximab) 
and Monafram® antiaggregants, as well as the antigenesis 
blocker Lucentis© (ranibizumab) (table 2). Another meth-
od is replacing IgG1 with IgG2 like in the cancer medicine 
Vectibix©(Panitumumab) specific to the eGFr marker 
(Her1) [57] (table 2). the IgG2 constant domain almost 
doesn’t bind to Fcγr receptors of the killer cells at all: 
therefore, antibodies of this subclass cannot cause ADcc.
A more universal approach involves the directed mu-
tagenesis of constant domain binding sites with c1q and 
Fcγr cell receptors. Directed mutagenesis was made pos-
sible due to the accurate mapping of Fcγr binding sites on 
the IgG1 constant domains [58]. researchers managed to 
obtain a whole spectrum of mutant MAb from antibodies 
which barely bound to Fcγr and c1q and are therefore not 
able to cause ADcc and cDc, up to high-affinity antibod-
ies characterized by a whole range of reactions caused by 
those two mechanisms [59–61]. researchers also created 
MAb variants that were not able to bind to c1q and cause 
reactions of the complement but could retain a high affin-
ity of binding to Fcγr receptors and the ability to cause 
ADcc [50]. the important result of that investigation was 
the creation of MAb (S239D/I332e/A330L) which could 
readily bind not only to the rare homozygotic allele of 
FcγrIII-158V/V (20% of patients), but also to more ubiq-
uitous alleles, such as FcγrIII-158V/F (45% of patients) 
and FcγrIII-158F/F (35% of patients). the construction of 
therapeutic antibodies with effector functions independent 
of patients’ polymorphism makes it possible to successfully 
treat all patients with medicines such as Herceptin© (tras-
tuzumab) and rituxan© (rituximab).
IgG contains only 3% of carbohydrate (Fig. 1); however, 
in spite of its insignificant content, this component plays a 
very important role in the performance of antibody effec-
tor functions. IgG contains two branched oligosaccharide 
chains, each of which is joined through a nitrogen atom to 
Asn297 residue in the constant СН2-domain (Fig. 3). the 
carbohydrate composition is characterized by high species 
specificity and varies within one species. the glycosyla-
tion of synthetic (or constructed) antibodies depends on the 
system in which they were prepared, the selected clone, 
and the separation system. therefore, the “incorrect” gly-
cosylation of therapeutic antibodies obtained in xenogenic 
systems (see Section 8) can cause an immune response, al-
lergic reactions, and favors the rapid removal of these an-
tibodies from the human blood flow [62]. Oligosaccharides 
(glycans) are known to be the key components in the IgG 
composition, because they provide the optimal binding of 
IgG constant domains with the Fcγr receptors mediating 
the effector functions. It has been proven recently that the 
removal of fucose from antibody carbohydrate increases 
the АcDc by over 50 times [63]. A decrease in the antibody 
efficiency in the organism (when compared to the in vitro 
experiments) forces the concentrations of the medicine in-
jected to increase. this situation is related to the inhibitory reVIeWS
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effect of fucosylated immunoglobulins in the blood plasma 
[64]. non-fucosylated therapeutic antibodies are character-
ized by a higher affinity to Fcγr receptors than fucosylated 
ones, which allows them to withstand the inhibitory effect 
of IgG circulating in the blood plasma and to be effective at 
lower concentrations [65]. 
All therapeutic antibodies approved for clinical appli-
cation are produced today in the cHO cells, in mouse my-
eloma cells such as nS0 and SP2/0, and in mouse hybri-
domes. Almost all of them have  fucosylated carbohydrate 
components and, as a result, non-optimal АcDc [66]. the 
fucosylation of the IgG carbohydrate component is carried 
out in mammal cells with α-1,6-fucosyl transferase (Fut8). 
Some mouse cell lines are characterized by a lower level of 
this ferment than cHO. However, the most efficient meth-
od to eliminate fucose is inactivating the Fut8 gene. cHO 
lines with inactivated Fut8 genes allow the construction 
of non-fucosylated therapeutic antibodies with АcDc in-
creased 50–200 times [67]. the explanation of the role of 
the IgG carbohydrate component gave the impetus to a 
new direction in antibody engineering. today, technolo-
gies of antibody construction, taking into account the car-
bohydrate component, are making rapid progress [68]. this 
direction is considered the most promising for construct-
ing next-generation therapeutic antibodies with improved 
characteristics. 
6 . BISPECIFIC ANTIBODIES 
natural antibodies are monospecific, i.e., they bind to anti-
gens of only one species. Antibody engineering technologies 
allow bispecific antibodies (Fig. 3, 2, 4, 5, 8) with a specifici-
ty to two different antigens to be created [29, 69]. the first 
bispecific antibodies were produced by fusing two hybrid-
ome cell lines. the quadroma created yields a random mix-
ture of a target-oriented bispecific antibody and primary 
antibodies. then, the required variant is obtained in the 
course of a complicated separation. A range of approaches 
was offered to increase the production of bispecific mol-
ecules, for instance, the creation of an interspecific mouse 
quadrome in the course of pairing the light and heavy 
chains of one species [70] and delicate “knob-and-holes” 
technology [32]. two mutants were injected into the MAb 
cH3-domains: “the knob” for replacing the small amino-
acid residue (threonine) with a bulky amino-acid residue 
(tyrosine) and “the hole,” for reverse replacement. 
Fusing the hybridomes that produce two types of an-
tibodies routinely led to the formation of bispecific mol-
ecules, which could be clicked-up by “knob-and-hole.” 
chemical conjugation [71] is still considered the most popu-
lar method of bispecific antibody creation, in spite of disad-
vantages such as the necessity of chemical modifications, 
which are occasionally harmful to antibodies, and the prob-
lem of separating the variants obtained. 
the gene engineering methods allow the creation of 
bispecific MAb and their fragments, avoiding the prob-
lem of separating the complex mixture produced [9]. the 
streptavidin-biotin system, characterized by stable associ-
ation with a constant of КD 10-15 М dissociation, is tradition-
ally used for these purposes. We offered a barnase–barstar 
protein pair (Figs. 3, 4, 5) as a heterodimerization module. 
this protein pair is characterized by a rather stable asso-
ciation with the КD 10-14 М dissociation, almost just like the 
streptavidin-biotin system, but makes it possible to pro-
duce bispecific antibodies with an exact ratio of 1 : 1 or 1 : 2 
(trimer) and does not require any chemical modification of 
the components [72], which is essential for delicate proteins 
such as antibodies. recently, a new sophisticated method 
called “dock and lock” (the DnL-method) was developed to 
create bispecific antibodies [33] (see also Section 7). Anti-
bodies produced by this method are distinguished by good 
pharmacokinetic characteristics and bivalent binding with 
surface antigen; thus they can be regarded as perspective 
agents for radioimmunotherapy. However, the major dis-
advantage of this method is the low affinity of the (КD ~ 
10-9) complex, which requires additional stabilization by 
disulfide bonds. 
Bispecific antibodies were primarily used for retarget-
ing the cytotoxic immune cells on the pathologic targets. 
numerous bispecific antibodies were created: one identifi-
cation domain of an antibody was bound to a characteristic 
surface marker on the cancer cell, while another domain 
was bound to an activation receptor of the cytotoxic cells 
[69, 73]. IgG FcγrI (cD64), characteristic of monocytes, 
macrophages, and dendritic cells; IgA FcαrI (cD89), ex-
pressed largely in neutrocyte, macrophages, and acido-
cytes; and the cD3 marker of cytotoxic t-lymphocytes 
were used as receptors which can attract cytotoxic cells to 
the target. It should be noted that t-lymphocyte, one of the 
most efficient killer cells, cannot be attracted to antibodies 
due to a lack of Fcγ receptors. unfortunately, clinical test-
ing established the shortcomings of that method. Immune 
cells needed additional activation, an effect that appeared 
only at a 40- to 100-fold surplus of effector over the num-
ber of target cells and high dose of medicine, and, finally, 
high dose-limiting toxicity in medicines was observed [73, 
74]. the use of bispecific antibodies for attracting cytotoxic 
t-cells to the cancer targets by binding with cD3 was ef-
fective only upon local application [75] and on the adap-
tive transfer of t-cells processed by bispecific antibodies 
ex vivo [76]. 
Almost all those obstacles were overcome by virtue of a 
new generation of bispecific t-cell engagers (Bite), which 
represented recombinant bispecific single-chain antibodies 
composed of two scFv-fragments specific to the surface an-
tigen of the target cell and t-cell cD3 antigen. In contrast 
to the above-mentioned full-size bispecific MAb, Bite an-
tibodies do not require the additional activation of attract-
ed immune cells and have enough cytotoxicity at much less 
concentrations [77, 78]. Obviously, bispecific MAb, which 
retargets immune cells, can be a perspective direction 
especially for the treatment of cancerous blood diseases. 
clinical investigations show that the application of Blinatu-
momab (anti-cD19/anti-cD3) medicine in a concentration 
of 0.005 mg/m2/day leads to the complete elimination of 
cancer B-lymphocytes from the blood flow of non-Hodgkin 
lymphoma patients [79].
Analogous methods involving bispecific antibodies were 
used to retarget stem cells, viruses, and pathogens. Bispe-
cific antibodies, which identify the receptor of the СD45 
stem cells, and antigens, which become readily accessible in 44 | ActA nAturAe |  № 1 2009
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case of myocardial infarction [71], were suggested as a way 
to attract the stem cells to the myocard of an experimental 
animal suffering from a heart attack and for the regenera-
tion of vascularization. this approach allows the delivery 
of a greater number of cells than injections of the stem cell 
suspension directly into the myocard. the researchers also 
tried to use bispecific antibodies for directed delivery to 
adenovirus tumors for gene therapy [80] and to eliminate 
pathogens from the blood flow, retargeting them on the 
cr1 receptor on erythrocytes [81]. these investigations are 
far from complete and will be subject to clinical trials. 
the second considerable sphere of clinical application 
of bispecific antibodies is pretargeting with the follow-
ing directed delivery of toxins, chemotherapeutic agents, 
and radioactive isotopes to the cancer cells (Fig. 4). the 
idea of pretargeting with the following elimination “on a 
tip” is based on the desire to maximally decrease the glo-
bal toxic effect when using strong toxins and radionuclides 
at the cost of both less circulation time in the blood and a 
decrease in the toxin therapeutic concentration. For this 
purpose, at the first stage, antibodies that are focused on a 
target—for instance, a tumor—are injected into an organ-
ism; then, after the natural removal of antibodies unbound 
to the target, the second cytotoxic component (toxin, ra-
dionuclide) is injected and specifically binds to the injected 
antibodies (Fig. 4). Initially, unmarked bispecific antibodies 
were suggested to be used for pretargeting: one valency 
would be bound to the tumor antigen, while another va-
lency would be bound to the hapten carrying a radioactive 
isotope [82]. the disadvantage of this method is the mono-
valent non-optimal binding to the antigen, as well as the 
relatively low production of bispecific antibodies obtained 
from the myelome line cells. the gene-engineering meth-
ods made it possible to construct a range of truncated an-
tibody fragments for radioimmunotherapy, including mul-
tivalent fragments (see Sections 1, 2, and 7), which led to a 
significant improvement in the pharmacokinetic properties 
of the targeting antibodies, specificity, and resolution of 
the method [83].
the third direction, which requires the construction of 
bispecific antibodies, is the simultaneous binding of two 
different antigenic determinants on one target. the high-
Fig. 4. Scheme of two‑stage 
target‑killing technologies.
(1) Pretargeting using 
antibodies with the following 
target killing by the involved 
A agent. 
(2) Preliminary delivery of 
E ferment to the target. At 
the second stage, E ferment 
transforms the nonactive 
medicine precursor into 
an active form (ADEPT, 
antibody‑directed enzyme 
pro‑drug therapy).reVIeWS
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er density of the surface antigen on the target cells com-
pared to the nonpathogenic cells is an essential condition 
for using this antigen for targeting; this provides specific 
action on the target and the safety of the whole organism. 
the number of molecules on the cell's surface is often in-
sufficient. In this case, one way to increase the specificity 
of targeting on the cancer cell and the time of antibody re-
tention on the target is to construct bispecific antibodies 
capable of simultaneous binding with two different tumor-
associating antigens expressed on the same cancer cell [72, 
84]. this method is important, because additional surface 
antigens can appear in the treatment process in response 
to the blocking of eGFr or Her2/neu receptors and cause 
resistance to medicines such as trastuzumab, cetuximab, 
and Panitumumab. recently, it was shown that resistance 
mechanisms may be activated due to a surplus of other ty-
rosine kinase receptors (IGF-rI, c-Met, ron, etc.), which 
activate the same signaling pathways as eGFr and Her2/
neu, bypassing the blocked receptors [85]. using bispecif-
ic antibodies for the simultaneous blocking of eGFr and 
IGF-1r significantly intensified the response of cancer 
cells when compared with monospecific antibodies [12]. 
this combined action on several surface antigens can block 
surplus signaling pathways in the cancer cell and lead to a 
more successful treatment. A combined effect is also pro-
duced by bispecific antibodies such as “intrabodies,” which 
are specific to the VeGF-r2 and tie-2 angiogenesis recep-
tors. the simultaneous blocking of two angiogenesis path-
ways by intrabodies intensifies the inhibition of angiogen-
esis and tumor growth more significantly than the blocking 
of only one pathway [86]. 
7 . IMMuNOCONJuGATES 
the goal of achieving a “magic bullet” and the low efficien-
cy of “unloaded” antibodies relative to the targets induced 
researchers to conjugate antibodies with other effector 
molecules (Fig. 3): radioisotopes, toxins, interleukins, and 
ferments activating medical products. In these immuno-
conjugates, antibodies usually act as a targeting component 
which delivers an active (cytotoxic) or diagnostic agent to 
the target. chemical conjugation methods are commonly 
used for the conjugation of low-molecular agents, for in-
stance, radioisotopes or low-molecular fluorescent dyes [11, 
87]. cell-penetrating peptides (ccP), capable of penetrat-
ing the membrane and transferring other proteins inside 
a cell, are conjugated to antibodies in the tumor by gene 
engineering in order to increase the penetration degree of 
radioimmunoconjugates. the most efficient cell-penetrat-
ing peptides are penetratine, which represents oligopep-
tide (43–58 a.r.) from the homeodomain of the drosophila 
Antp protein, and tAt, which is an oligopeptide (49–57 
а.r.) from the transactivator of HIV transcription. Mini-an-
tibody radioimmunoconjugates, which are specific to the 
tAG72 tumor antigen and provided with penetratine or 
tAt oligopeptide, are accumulated 2.5–3 times better in 
the tumors of xenographic mice [88].
In oncology, two medical products are approved for the 
radioimmunotherapy of non-Hodgkin’s lymphoma: Bexx-
ar©, which is mouse IgG2a conjugated with β-emmiter of 
medium energy 131I (the penetration radius is 1 mm), and 
Zevalin©, which is mouse IgG1 conjugated with β-emmiter 
of high energy 90Y (the penetration radius is 11 mm) (table 
2). currently, investigations are focused on replacing mouse 
antibodies as targeting agents for radioimmunotherapy 
with less immunogenic fragments (see Section 3), as well 
as on developing pretargeting technologies to decrease the 
general radiation load on the organism (see Section 6). 
to achieve these goals, the heterodimerization module 
is required, as with the creation of bispecific antibodies. 
today the streptavidin-biotin system [89], which is well-
proven for a range of analytical applications, is being used 
for this purpose. However, using this system in the human 
organism is limited by its high content of endogenic biotite, 
which can compete with the biotin-modified components. 
We have offered a new strategy of two-stage delivery 
based on ribonuclease, barnase, and its inhibitor, barstar 
[30, 31]. As was mentioned earlier that, these two proteins 
(110 and 89 а.r.) form the (КD ~ 10-14 М) complex, which is 
similar in resistance to the streptavidin-biotin system [90]. 
the proteins are stable; well-soluble; resistant to proteases; 
and, thus, compatible to the bacterial expression system. 
the n- and c-tails of both proteins occur outside the in-
teraction area and are readily accessible for gene engineer-
ing fusion with the targeting mini-antibodies and cytotoxic 
agents [91, 92]. the principal possibility of the two-stage 
delivery of an active agent to the cancer cells was shown 
using the example of recombinant mini-antibodies, Her2/
neu specific to the cancer surface antigen and conjugated 
with barstar, and a visualization component such as a re-
combinant fluorescent protein—eGFP—conjugated to bar-
nase [31]. the essential advantage of the barnase–barstar 
module is the exact 1 : 1 ratio of components in the complex 
and the absence of self-aggregation, as well as the high af-
finity of interaction, which exceeds the values of all other 
dimerization systems (except for the streptavidin-biotin 
one). But, in contrast to the streptavidin-biotin system, the 
use of a heterodimerization module is based on gene en-
gineering technologies and does not require any covalent 
modifications. 
the DnL method is of special interest among other 
methods developed for pretargeting a target cell [33]. this 
technology is based on the specific protein–protein inter-
action of a dimeric regulatory subunit (rII) of cyclic ad-
enosine monophosphate-dependent protein kinase and the 
anchoring domain (amphipathic helix from 14–18 a.r.) of 
an A kinase anchor protein. A trivalent bispecific antibody 
focused on carcinoembryonic antigen (ceA, tumor antigen) 
and hapten histamine-succinyl-glycine was constructed on 
the basis of those polypeptides and the Fab-fragments of 
two different antibodies. At the first stage of directed deliv-
ery (Fig. 4), the “landing” component provides the bivalent 
interaction with the tumor antigen. At the second stage, the 
“lock,” connected by the anchoring domain to the “dock,” is 
bound to the hapten, which is marked by radioactive 99mТс. 
the relatively low affinity of the (КD ~ 10-9) complex re-
quires additional stabilization by disulfide bonds. One more 
disadvantage is the complexity of the trivalent antibody 
construction composed of five different protein chains. In 
spite of these problems, pretargeting made it possible to 
increase the accumulation of the radioactive mark on the 46 | ActA nAturAe |  № 1 2009
reVIeWS
tumors grafted to mice by ~25 times when compared to the 
one-stage injection [33]. today, this method can replace the 
bispecific MAb and streptavidin-biotin system commonly 
used for pretargeting [89]. Indeed, the trivalent bispecific 
antibodies created by the “dock and lock” method have a 
range of undeniable advantages for this application: biva-
lent binding with a tumor antigen, which intensifies the in-
teraction and increases the time of retention on the patho-
genic cells; the absence of the antibody effector functions, 
which significantly reduces unwanted side effects; the rap-
id removal of the targeting component from the organism, 
which decreases the waiting time for the second stage—the 
injection of the radioactive isotope proper—from 6–7 days 
to a few hours [93].  
Much research is devoted to using different strong tox-
ins for directed action on the target cells; 44% of medicines 
with anti-tumor antibodies subject to clinical trials are im-
munoconjugates or recombinant proteins. However, only 
one medicine, Mylotarg©, which represents a humanized 
anti- cD33-antibody Gentuzumab chemically conjugated 
with cytotoxic antibiotic calicheamicin, was approved for 
clinical application (table 2). this disproportion reflects 
all the objective problems appearing in researchers’ way 
when developing such an attractive idea. At the first stage 
of investigation, immunotoxins constructed on the basis of 
bacterial toxins or doxorubicin antibiotic were character-
ized by high systematic toxicity and a great number of side 
effects. using antibodies loaded with strong toxins requires 
a more careful approach to selecting a target, because it 
is essential to avoid delivering cytotoxic agents to normal 
cells. It is preferable to target immunotoxins on antigens 
that are not expressed on normal cells but are readily ex-
pressed on the surface of tumorous cells. unbound immu-
notoxin should be eliminated from the blood flow as soon as 
possible. the rapid internalization of antigen after binding 
with immunotoxin is preferable as well. Moreover, because 
a medicine’s efficiency is related to the compound's toxicity 
level, it is expeditious to use toxins with a Ic50 level which 
ranges within the nano- and picomolar concentrations. to 
date, researchers have the following range of required tox-
ins: auristatin and calicheamicin, as well as such protein 
toxins as pseudomonade ricin and diphtherin [94]. 
All these ideas were taken into consideration in design-
ing Mylotarg© (table 2). Humanized MAb Gentuzumab is 
specific to surface cD3 antigen, which is hyperexpressed 
on the surface of malignant cells caused by acute myeloid 
leukemia; therefore, a maximum non-toxic dose of this 
medicine is rather high and attains 9 mg/m2. cD33 is read-
ily internalized, and the therapeutic response depends not 
on the antigen expression level but on the stage of the cell 
cycle and multi-drug resistance. the cytotoxic component 
of this immunotoxin is the antibiotic calicheamicin, which 
binds to the DnA groove and breaks it. the toxicity of this 
antibiotic is characterized by the Ic50 value, which is within 
the low nM concentration.
the cytotoxicity of antibiotics from the auristatin and 
maytansinoid group has another nature. these antibiotics 
bind to α-tubulin and break the polymerization of micro-
tubules, which causes cell-cycle block and cell death. cD20, 
cD30, cD70, PSMA (prostate-specific membrane antigen), 
Her2/neu, e-selectin, and LewisY cell markers are used as 
the targets for immunoconjugates. As in the case with ra-
dioimmunotherapy, immunoconjugates are more efficient 
for treating hematologic types of cancer and are inefficient 
for the treatment of solid tumors. 
currently, immunotoxins derived from truncated 
pseudomonade A exotoxin and diphtherin are subject to 
clinical testing. the action mechanism of these immuno-
toxins is based on the catalytic ADP-ribosilation of factor 
2, inhibiting the translation. the first and the second gen-
erations of those multidomain proteins were characterized 
by high systematic toxicity, which significantly decreased 
after the elimination of the domains responsible for bind-
ing with the cells. the major advantage of these proteins 
is their high toxicity in the pM concentrations: only a few 
molecules are needed to kill a cell. the disadvantage is 
the immunogenicity and presence of side effects such as 
the capillary leak syndrome. to inhibit immunogenicity, 
A. Pastan, a pioneer researcher in immunotoxins, carried 
out hard work focused on the deimmunization of truncat-
ed pseudomonade РЕ38 toxin with the complete retention 
of its toxicity [95]. the high intensity of his investigations 
aimed at creating medicines on the basis of immunotoxins 
will likely make them available for clinical use very soon. 
Attempts to use rnAase as toxins were made much lat-
er, at the end of the 1990s. the researchers obtained conju-
gates of bull pancreatic rnAase and anti-eGFr mouse an-
tibodies [96], as well as a recombinant protein on the basis 
of human pancreatic rnAase and single chain anti-trans-
ferrin receptor mini-antibodies [97]. Human pancreatic 
rnAase was conjugated with a humanized mini-antibody 
to decrease immunogenicity [98]. the same authors were 
the first to offer the term “ImmunornAase.” today, im-
munornAase is of great interest [99–102]. rnAase draws 
the attention of researchers due to its accessibility, low 
immunogenicity, and absence of toxicity outside the cell. 
thus, it is quite possible that rnAase-based medicines will 
not be characterized by systematic toxicity, but the prob-
lem of internalization into the target cells remains unsolved. 
using human rnAase is significantly limited by inhibition 
by a natural inhibitor (rI) present in the cells. researchers 
produced mutants of human rnAase resistant to the in-
hibitor [103] by directed mutagenesis and offered a search 
for the appropriate rnAase of other origins [104]. current-
ly, the clinical testing of onconase, the first rnAase used 
for cancer therapy [105], is drawing towards a successful 
completion. this positively charged protein (104 a.r) from 
frogs belongs to the amphibian A ribonuclease superfamily 
and has cytostatic and cytotoxic action largely on cancer 
cells. this selectiveness is likely related to the strong posi-
tive charge of onconase and the fast metabolism of the can-
cer cells [105].
In our laboratory we used the bacterial ribonuclease of 
barnase to create immunotoxin [30, 45, 106, 107]. this small, 
stable, and well-soluble protein is resistant to the natural 
inhibitor of human rnAase. earlier, we established that 
the barnase of multidomain recombinant proteins plays 
the role of internal chaperone, provides the correct domain 
coiling, and favors the stability and good solubility of pro-
tein [108]. Barnase, which is toxic for cells, has been used reVIeWS
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to create a zero-background vector [90]. the constructed 
immunodibarnase contains two barnase molecules and a 
humanized mini-antibody specific to the internalized can-
cer Her2/neu marker (Fig. 5, 1). the in vitro experiments 
show that providing a toxic barnase agent that addresses 
the mini-antibody significantly increases the efficiency of 
action on the cancer cells. the anti-cancer mini-antibody 
delivers barnase on the surface of cancer cells (Fig. 5, 2(А)) 
and provides for its penetration into the cell (Fig. 5, 2(В)), 
where it exposes its toxic nature. Immunodibarnase (1.8 
nM) causes the apoptosis of 50% of Her2/neu-positive 
cells, whereas Her2/neu-negative cells require a concen-
tration 250–300 times higher (Fig. 5, 3). the cytotoxic ef-
fect of barnase depleted in mini-antibodies is non-specific 
and ~1000 times less acute than the cytotoxic effect of im-
munodibarnase (Fig. 5, 3) [107]. Immunodibarnase can be a 
perspective agent for treating tumors thanks to its specific 
action on the cancer cell and low active concentration. 
rnAase circulating in the blood stream is nontoxic to 
the organism and becomes toxic only after penetrating 
into the cancer cell, where it plays the role of a so-called 
protoxin [99]. A similar idea would be to create nonactive 
pre-medicine which would be delivered to the target and 
then transformed into active form; this is being developed 
in different variants on the basis of ADePt technology 
(antibody-directed enzyme pro-drug therapy) (Fig. 4). the 
technology is based on the preliminary directed delivery of 
a ferment conjugated with the antibody to the target cells. 
targeting  the delivery is provided by the especificity of 
antibody to the cell antigen. At the next stage, in the mi-
croenvironment of the target, the injected non-active pre-
cursor of the medicine is transformed into an active form 
by a ferment delivered earlier and kills the surrounding 
cells. β-lactamase, G2 carboxypeptidase, and others are 
used as ferments at this stage [86, 109, 110].
creating anti-idiotypic antibodies with definite catalyt-
ic functions—so-called abzymes—which can perform the 
functions of antibodies and are characterized by fermen-
tation activity is a new prospective scientific direction of 
gene engineering. Modifying the anti-idiotypic antibody 
scFv-fragments, combined with the use of phage libraries, 
makes it possible to select abzymes with preprogrammed 
properties [111, 112].  
Some cytotoxins (for instance, IL-2, IL-12, tnFα, IFnγ, 
GM-cSF) have immunomodulatory and antitumoral value. 
unfortunately, using these proteins as medicines is hardly 
possible due to their high systemic toxicity in active con-
centrations, fast decomposition and removal from the or-
ganism, and the undirected and nonspecific action on the 
tumor cells. the conjugation of antibodies with cytotox-
ins and the creation of immunocytotoxins makes it pos-
sible to overcome the limits pointed out. Investigating in-
terleukin-2 therapeutic and adjuvant properties brought 
about the greatest step forward. For instance, we have ob-
tained encouraging results in the course of clinical trials 
of recombinant immunocytokines constructed on the basis 
of interleukin-2, anti-cancer humanized antibodies (GD2 
disialoganglizid and the epithelial cell adhesion molecule 
Fig. 5. Immunodibarnase as a perspective agent for treating malignant neoplasms [105] . (1) Scheme of immunodibarnase structure. (2) Interaction of 
immunodibarnase with the cells expressing the HER2/neu cancer marker: surface binding at 4°С (А) and internalization at 37°С (В). (3) Cytotoxicity of 
immunodibarnase for the cells with hyperexpression of the HER2/neu cancer marker.48 | ActA nAturAe |  № 1 2009
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epcAM), and anti-angiogenesis antibodies (eDB and the 
extra domain B of fibronectin) for treating melanoma, neu-
roblastoma, and non-Hodgkin’s lymphoma [113, 114] and 
on the basis of interleukin-2 conjugated with anti-cD20 
antibody for treating B-cell malignancy [115]. using im-
munocytokines helps increase the effectiveness of chemo-
therapy as well [116]. 
conjugates of antibodies with different fluorescent 
probes are often used in immunology for in vitro investiga-
tions. Introducing a powerful instrument such as fluores-
cent proteins by molecular biology (2008 nobel Prize, Dr. 
Osamu Shimomura, Dr. Martin chalfie, and Dr. roger Y. 
tsien) allows us to observe the vital activity of the cells on 
a real-time basis. Japanese researchers created a system 
for visualizing living cancer cells in the organism based on 
the pH-activation fluorescent agent directed to the target 
cell by an anti-cancer internalized antibody [117]. Fluores-
cence is observed only if the agent occurs in the lysosomes 
of the living cancer cell and disappears when it dies. the 
method's specificity is 99%. these investigations are far 
from being used in therapy, but they enable us to discover 
the new abilities of immunoglobulin conjugates. 
8 . RECOMBINANT ANTIBODy CONSTRuCTION SySTEM .
today, producing stable and high-affinity MAb in a suf-
ficient amount for pre-clinical and clinical investigations is 
a “bottleneck” for the wider application of these therapeu-
tic compounds. the rapid growth in demand for antibodies 
and their quality has led to the development of numerous 
systems for producing antibodies and their fragments on 
the basis of Gram-positive (Bacillus) and Gram-negative 
(escherichia) bacteria, ferments, filamentous fungi, and 
the cell lines of insects and mammals [118–120]. High-tech-
nological systems such as bacterial and ferment producers, 
which favor the overgrowth of biomass in fermenters and 
the production of highly efficient recombinant proteins, can 
solve the problem of creating truncated MAb fragments, 
non-glycosylated Fab-fragments, and scFv provided, as a 
rule, with special tail peptides for fast activation on aff-
ine sorbent. currently, antibodies are created in transgenic 
plants and animals which are appropriate for the produc-
tion of full-size antibodies [72, 121]. the expression system 
is created on the surface of bacterial cells (so called “e-clon-
al” antibodies) used for both full-size and divalent formats 
[122] for the fast production and selection of full-size anti-
bodies. the glycosylation of antibodies in ferments, plants, 
and insects differs from that in a human being: therefore, 
antibodies obtained in those systems are applicable only for 
experimental investigations. today, therapeutic antibodies 
are produced in transgenic mice, whose immunoglobulic 
locuses are inactivated and replaced with the genes of hu-
man immunoglobulins [10, 123]. the most well-known mice 
transgenic lines are as follows: Xenomouse (Abgenix, www.
abgenix.com), HuMab mouse (GenPharm, www.genpharm.
ca), and tc mouse and KM mouse (Kirin Brewery com-
pany, www.medarex.com). Medicines with MAb created in 
these producers are characterized by low immunogenicity 
due to xenogenic post-translation modifications and, pri-
marily, to glycosylation specifics. Moreover, the research-
ers are developing new technologies which would allow the 
production of MAb with a human profile of glycosylation in 
ferments, insects, and transgenic plants [124, 125]. 
9 . CONCLuSIONS AND PROSPECTS .
In the early 21st century, one hundred years after Ilya 
Mechnikov and Paul ehrlich, the founders of the current 
immunity theory (1908), received the nobel Prize, knowl-
edge about the delicate molecular mechanisms of anti-
body functioning and interaction with the organism’s pro-
tective systems has made the greatest step forward. this 
progress is provided by the innovative technologies used in 
the course of scientific investigations and the accumulation 
and systematization of large amounts of information. the 
quick development of bioinformatics allows us to model the 
compounds with preprogrammed properties, while revolu-
tionary progress in genetic and cell engineering technolo-
gies makes it possible to create biotechnological producers 
of therapeutic medicines. 
Modern technologies make it possible to modify the anti-
body properties depending on the situation and use all their 
functions. thanks to gene engineering, researchers manage 
to decompose antibodies and compose new constructions. 
truncated antibodies, focused on binding with a target and 
compatible with a bacterial expression, are used for pro-
ducing a wide range of compounds meant for the highly ef-
ficient delivery of active agents. researchers have created 
clone libraries of immunoglobulin fragments and highly ef-
ficient screening systems. Moreover, a new scientific direc-
tion has appeared; it is focused on constructing framework 
molecules, also called scaffolds (as an alternative to anti-
bodies), which are characterized by an analogous ability 
to specifically bind. undoubtedly, this sphere will develop 
in both directions: the construction of the next genera-
tion of recombinant truncated humanized antibodies with 
multivalent binding characterized by improved pharma-
cokinetic properties [34, 126] and the creation of alterna-
tive framework constructions [127]. truncated antibodies 
that are depleted in constant domains are widely used in 
radioimmunotherapy for the directed delivery of radioac-
tive isotopes as immunotoxin components in oncology and 
as specific blockers of targets in cardiosurgery. 
the bispecific antibodies in both truncated and full-
sized formats have great potential. these antibodies have 
been used in radioimmunotherapy for a rather long time, 
and new technologies can only modify and improve the 
currently available and well-established methods of one- 
and two-stage delivery of radioisotopes to a target [93]. On 
the contrary, using bispecific antibodies in the sphere of 
cell immunotherapy has just begun [128], and researchers 
have a wide field of experimental and clinical investiga-
tions. the high variability of the cancer cells and the prob-
lem of resistance to therapy generate a need for complex 
treatments and the use of several medicines with differ-
ent mechanisms of action. Bispecific antibodies, which can 
strike two targets simultaneously and block two metabolic 
pathways, are irreplaceable in this case as well. 
new technologies for controlling the functions of the 
antibody constant domain are reaching new heights. the 
development of constant domain engineering and, in par-
ticular, carbohydrate MAb engineering testifies to a return reVIeWS
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to “traditions” and growth in interest in the antibody ef-
fector functions and full-size MAb, because they attract all 
the protection systems of the organism to the pathological 
center [129]. 
One scientific direction which is quite promising from 
the technological standpoint is the creation of hybrid bio-
compatible nanoparticles from organic and inorganic mate-
rial. Providing these nanoparticles with antibody particles 
will ensure high-accuracy targeting. Semiconductive fluo-
rescent crystals (“quantum dots”), magnetic nanoparticles, 
gold colloids, and fullerene derivative delivered with their 
help will carry medicinal compounds and allow additional 
external action on the targets by means of laser, acoustic, 
and microwave radiation [130, 131]. this new generation 
of multifunctional nanoconstructions should have complex 
properties that cannot be used separately. this combined 
action on the tumors will help achieve a whole that is truly 
more than the sum of its parts. 
today, only 15 out of 266 applied medical targets found 
in the human genome are used as antigens in making ther-
apeutic antibodies to treat different diseases, and almost 
all of them are surface cell antigens [132]. Accumulating 
knowledge about cancer biology will make it possible to 
reveal new cell chains and directionally create multifunc-
tional constructions for accurate action against the targets 
responsible for the profileration, conglutination, metabo-
lism, distribution, and other mechanisms of malignant neo-
plasms (see, for instance, [133]). 
It can be expected that the future success of the clinical 
application of antibodies will depend to a great extent on 
the development of new targets for them in the course of 
accumulating new knowledge about the mechanisms and 
molecular participants of the pathological processes. 
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